Chronic treatment with a GLP-2 receptor agonist increased glucose absorption in rat intestines by enlarging them, according to a 2026 laboratory study published in Physiological Reports. Adding a GIP receptor agonist didn’t boost glucose absorption further, though it did increase blood flow to the intestines. Gram Research analysis shows these findings suggest long-term hormone treatments might eventually help people absorb nutrients better, but human studies are needed before any medical applications.
Scientists discovered that two natural gut hormones, GLP-2 and GIP, work together to help your intestines absorb more glucose (sugar) when given as long-term treatments. In a study using rat intestines, researchers found that chronic treatment with a GLP-2 receptor agonist increased glucose absorption by enlarging the intestines. When combined with a GIP receptor agonist, the effect didn’t improve further, but the GIP treatment did increase blood flow to the intestines. According to Gram Research analysis, these findings suggest that boosting these hormones over time could help the body process nutrients more efficiently, though the study was conducted in laboratory conditions and more human research is needed.
Key Statistics
A 2026 laboratory study in Physiological Reports found that chronic GLP-2 receptor agonist treatment increased glucose absorption in isolated rat intestines by enlarging the intestinal tissue, though combining it with a GIP receptor agonist provided no additional benefit for glucose absorption.
According to research reviewed by Gram, the GIP receptor agonist increased blood flow to the intestines in rats both alone and when combined with the GLP-2 agonist, suggesting the two hormones work through different mechanisms to potentially enhance nutrient processing.
A 2026 study in Physiological Reports found that acute doses of GLP-2 and GIP hormones had no significant effect on nutrient absorption in rat intestines, indicating that long-term exposure to these hormones is necessary for them to change intestinal function.
The Quick Take
- What they studied: Whether two gut hormones called GLP-2 and GIP can help the intestines absorb more glucose (blood sugar) when given as long-term treatments versus quick doses.
- Who participated: Male laboratory rats whose intestines were studied in controlled laboratory conditions using a special perfusion system that mimics how blood flows through the gut.
- Key finding: Long-term treatment with a GLP-2 hormone agonist increased glucose absorption by making the intestines larger, but adding a GIP agonist didn’t boost this effect further. The GIP treatment alone did increase blood flow to the intestines.
- What it means for you: These findings suggest that long-term hormone treatments might help people absorb nutrients better, but this is early laboratory research in rats. More studies in humans are needed before any medical applications. People with digestive issues should consult their doctor about potential future treatments.
The Research Details
Researchers used isolated rat intestines connected to a perfusion system, essentially a machine that pumped blood through the intestines like the body normally does. They tested three different treatment approaches: chronic (long-term) injections given 6 days before the experiment, subacute injections given 2 hours before, and acute doses delivered directly into the blood during the experiment. For chronic and subacute treatments, they used long-acting versions of GLP-2 and GIP receptor agonists (drugs that activate these hormone receptors). For acute treatments, they used the natural hormones themselves. The researchers measured how much glucose, fats, and amino acids the intestines absorbed under different conditions.
In separate experiments, they changed the blood flow rate through the intestines to see how this affected nutrient absorption. They also measured blood flow to the intestines in living rats using a special probe. This multi-layered approach allowed them to understand not just whether the hormones worked, but how they worked, whether by changing intestine size, blood flow, or other mechanisms.
The study was carefully controlled, with constant blood flow rates during most experiments so researchers could isolate the effects of the hormones themselves. This laboratory approach allowed precise measurement but doesn’t capture the complexity of how these hormones work in living, moving bodies.
Using isolated intestines allows scientists to study nutrient absorption in a controlled way without the complications of a whole living body. This approach helps identify which hormones affect which nutrients and through what mechanisms. Understanding these basic mechanisms in animal models is an important first step before testing in humans. The findings could eventually lead to new treatments for digestive disorders or malabsorption problems.
This is a well-designed laboratory study with careful controls and multiple measurement approaches. However, it was conducted in rats, not humans, so results may not directly apply to people. The study measured specific, objective outcomes (nutrient absorption rates and blood flow), which strengthens reliability. The researchers tested multiple conditions and combinations, providing comprehensive data. The main limitation is that laboratory intestines don’t experience the full complexity of digestion in living bodies, including movement, hormonal signals from other organs, and the microbiome.
What the Results Show
Chronic GLP-2 receptor agonist treatment significantly increased glucose absorption in the rat intestines. This increase appeared to happen because the treatment made the intestines larger, more surface area means more room to absorb nutrients. When researchers combined the GLP-2 agonist with a GIP agonist for chronic treatment, glucose absorption didn’t increase any further than the GLP-2 treatment alone, suggesting the combination didn’t provide added benefit for this outcome.
The GIP receptor agonist alone increased blood flow to the intestines, both when given alone and when combined with the GLP-2 agonist. Interestingly, the GLP-2 agonist by itself didn’t significantly change blood flow. This suggests the two hormones work through different mechanisms, GLP-2 works by enlarging the intestines, while GIP works by increasing blood flow.
None of the treatments affected how well the intestines absorbed fats or amino acids (proteins), only glucose absorption improved. This specificity suggests these hormones have targeted effects on different types of nutrients. When researchers increased the blood flow rate artificially, nutrient absorption increased across the board, confirming that blood flow is important for nutrient absorption.
The study revealed that acute doses of the hormones (given directly during the experiment) had no significant effect on nutrient absorption, unlike the chronic treatments. This suggests that long-term exposure to these hormones is necessary for them to change how the intestines work. The finding that blood flow increases with the GIP agonist is important because better blood flow could theoretically help deliver absorbed nutrients throughout the body more efficiently. The fact that combining both agonists didn’t improve glucose absorption beyond the GLP-2 agonist alone suggests there may be a limit to how much these hormones can enhance absorption, or that they may work through overlapping pathways.
Previous research suggested that GLP-2 and GIP might regulate intestinal nutrient absorption, but this study provides more specific evidence about how they work. The finding that chronic GLP-2 treatment increases intestinal size aligns with what scientists already knew about this hormone’s effects on gut growth. However, the detailed comparison of chronic versus acute effects and the specific finding that GIP increases blood flow without further boosting glucose absorption adds new information. The study’s focus on isolated intestines provides mechanistic detail that complements previous whole-body studies.
This research was conducted in rats, not humans, so results may not directly translate to people. The intestines were isolated and perfused artificially, which doesn’t capture the full complexity of digestion in a living body, including stomach movement, hormonal signals from other organs, the gut microbiome, and nervous system control. The study didn’t specify the exact sample size, making it difficult to assess statistical power. The research used male rats only, so results may not apply equally to females. The study measured only glucose, fats, and amino acids; other nutrients weren’t tested. Finally, this is basic laboratory research, and much more work would be needed before these findings could lead to human treatments.
The Bottom Line
This is early-stage laboratory research, so no direct recommendations for people can be made yet. The findings suggest that GLP-2 receptor agonists might eventually be useful for improving nutrient absorption in certain digestive conditions, but human studies are needed first. People with malabsorption disorders or digestive issues should continue following their doctor’s current treatment plans. Moderate confidence in these findings as a foundation for future research, but low confidence for immediate human application.
Researchers studying digestive health, pharmaceutical companies developing new treatments for malabsorption disorders, and people with conditions affecting nutrient absorption should find this research interesting. People with celiac disease, Crohn’s disease, or other digestive disorders might eventually benefit from treatments based on these findings. Healthcare providers treating digestive disorders should be aware of this research direction. People without digestive problems don’t need to change anything based on this study.
This is basic research, so any practical applications are likely years away. If these findings lead to human trials, it would typically take 5-10 years or more before a new treatment could become available. Even then, treatments would likely be targeted at specific digestive disorders rather than general use. Researchers will need to conduct additional animal studies, then human safety and effectiveness trials before any clinical application.
Frequently Asked Questions
How do GLP-2 and GIP hormones help with nutrient absorption?
According to 2026 research, GLP-2 increases nutrient absorption by enlarging the intestines, while GIP increases blood flow to the intestines. Both mechanisms theoretically help the body absorb more nutrients, though the study showed GLP-2 specifically boosted glucose absorption in rats.
Can I take GLP-2 or GIP treatments now to absorb nutrients better?
These findings are from laboratory rat studies, not human trials. No GLP-2 or GIP treatments for nutrient absorption are currently available for general use. People with digestive disorders should consult their doctor about existing treatment options.
Does combining GLP-2 and GIP treatments work better than using them separately?
In this rat study, combining both hormones didn’t improve glucose absorption beyond using GLP-2 alone, suggesting the combination may not provide added benefit. However, the GIP treatment did increase blood flow, which could have other benefits not measured in this study.
When will treatments based on this research be available for humans?
This is early-stage laboratory research. If it leads to human trials, treatments would likely take 5-10 years or more to develop and approve. Any resulting treatments would probably target specific digestive disorders rather than general use.
Who would benefit most from GLP-2 or GIP-based treatments?
People with malabsorption disorders like celiac disease, Crohn’s disease, or other digestive conditions affecting nutrient absorption might eventually benefit. However, more research is needed to determine safety and effectiveness in humans before any clinical recommendations can be made.
Want to Apply This Research?
- Users interested in digestive health could track daily nutrient absorption indicators: energy levels (1-10 scale), digestive comfort (1-10 scale), and specific nutrient intake from food logs. This creates a baseline for comparing before and after any future treatments based on this research.
- While waiting for potential future treatments, users can optimize current nutrient absorption by eating smaller, more frequent meals; staying hydrated; and tracking which foods cause digestive discomfort. The app could remind users to log these factors and identify personal patterns.
- Set up a long-term digestive health dashboard tracking energy, digestion comfort, and nutrient intake patterns. When new GLP-2 or GIP-based treatments become available, users can compare their baseline metrics to post-treatment metrics to assess personal effectiveness. This creates individual evidence for whether a treatment works for them specifically.
This article summarizes laboratory research conducted in rats and does not represent medical advice. The findings are preliminary and have not been tested in humans. Anyone with digestive disorders, malabsorption issues, or concerns about nutrient absorption should consult with a qualified healthcare provider before making any changes to their diet or treatment plan. Do not attempt to self-treat based on this research. Future treatments based on these findings may take many years to develop and approve for human use.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
